biotech

biotech Articles

Verastem saw perhaps the biggest gain in the market Wednesday after the company announced positive late-stage results.
Sarepta Therapeutics saw its shares make a handy gain on Wednesday after the firm announced muscle biopsy results from its mid-stage study for the treatment of Duchenne muscular dystrophy.
Insmed has filed with the SEC for a secondary offering. This follows a surge in the share price following positive late-stage results from its clinical study in the treatment of nontuberculous...
Cellectis shares tumbled early on Tuesday after the firm announced that a couple of its early-stage studies were put on hold by the FDA.
Insmed saw its shares more than double early on Tuesday after the firm released late-stage results from its clinical study in the treatment of nontuberculous mycobacteria lung disease.
Otonomy saw its shares crater after the firm announced results for its Averts-1 late-stage trial of Otividex in patients with Ménière’s disease.
ImmunoGen has decided to partner with Jazz Pharmaceuticals for the development and commercialization of two early-stage, hematology-related antibody-drug conjugate programs.
Acorda Therapeutics saw its shares get crushed early on Tuesday after the firm received a Refusal to File letter from the FDA in regards to its New Drug Application for Inbrija.
Gilead Sciences shares have been in a holding pattern for a while. Analysts have said that the firm needs to make a move to shake this situation, otherwise this could turn into something worse.
The August 15 short interest data have been compared with the previous report, and short interest moves in the selected biotech stocks were mixed.
Ultragenyx Pharmaceutical just hit a 52-week low and analysts have slashed and burned their price target expectations. This is after a late-stage trial did not live up to expectations.
Intra-Cellular Therapies saw its shares make an incredible gain early on Wednesday after the FDA gave a positive regulatory update on the firm’s schizophrenia program.
Gene therapy company Krystal Biotech has filed with the SEC regarding its initial public offering.
The quiet period for Sienna Biopharmaceuticals, Inc. (NASDAQ: SNNA) is over after its initial public offering. The Westlake Village, California-based company recently sold just 4,983,333 shares of...
Coherus Biosciences, Inc. (NASDAQ: CHRS) watched its shares jump on Monday after the company announced that it plans to raise up to $150 million in a two tranche private placement. A Singapore...